Get started
Author

José Luiz Pedrini

Observed names: J. L. Pedrini, J. Pedrini, J.L. Pedrini, JL Pedrini, Jose L. Pedrini, Jose Luiz Pedrini, José L. Pedrini, José Pedrini, PEDRINI, José L., Pedrini, Jose Luiz
Observed institutions: F. Hoffmann-La Roche AG, Universidade Federal de Ciências da Saúde de Porto Alegre, University of Liège, University of Mannheim, Charles University, Hospital de Sant Pau, Samsung Medical Center, Baylor University Medical Center, Charing Cross Hospital, Seoul National University Hospital, Taipei Veterans General Hospital, Ospedale "Santa Maria delle Croci" di Ravenna, AZ Klina, Clinique de Genolier, Roche (France), Hospital Amaral Carvalho, Hospital Nossa Senhora da Conceição, National Institute of Oncology, Ministério da Saúde, Hospital Ernesto Dornelles, Grupo Hospitalar Conceição, IRCCS Ospedale San Raffaele, Koo Foundation Sun Yat-Sen Cancer Center, Hospital da Mulher São Paulo, OZ Biosciences (France), Instituto Nacional del Cáncer, Hospital Santa Marcelina, Helios Hospital Berlin-Buch, Fondazione IRCCS Istituto Nazionale dei Tumori, Hospital of Prato, National Yang Ming University, Centro de Referência da Saúde da Mulher - Hospital da Mulher São Paulo, Imperial College London
ORCID: 0000-0003-1239-3238
Observed ORCID: 0000-0003-1239-3238
OpenAlex ID: A5038914061
Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer
2011 · José Baselga, Javier Cortés, et al. · New England Journal of Medicine · 2,585
PDF
Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial
2011 · Luca Gianni, Tadeusz Pienkowski, et al. · The Lancet Oncology · 2,467
Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study
2020 · Sandra M Swain, David Miles, et al. · The Lancet Oncology · 990
5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trial
2016 · Luca Gianni, Tadeusz Pienkowski, et al. · The Lancet Oncology · 936
Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer
2021 · D. Miles, J. Gligorov, et al. · Annals of Oncology · 786
PDF
Results of the CONFIRM Phase III Trial Comparing Fulvestrant 250 mg With Fulvestrant 500 mg in Postmenopausal Women With Estrogen Receptor–Positive Advanced Breast Cancer
2010 · Angelo Di Leo, Guy Jerusalem, et al. · Journal of Clinical Oncology · 644
Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial
2011 · Luca Gianni, Urania Dafni, et al. · The Lancet Oncology · 622
Final Overall Survival: Fulvestrant 500 mg vs 250 mg in the Randomized CONFIRM Trial
2013 · A. D. Leo, G. Jerusalem, et al. · JNCI Journal of the National Cancer Institute · 329
PDF
Trastuzumab deruxtecan versus trastuzumab emtansine in HER2-positive metastatic breast cancer: long-term survival analysis of the DESTINY-Breast03 trial
2024 · Javier Cortés, Sara A. Hurvitz, et al. · Nature Medicine · 204
Atezolizumab With Neoadjuvant Anti–Human Epidermal Growth Factor Receptor 2 Therapy and Chemotherapy in Human Epidermal Growth Factor Receptor 2–Positive Early Breast Cancer: Primary Results of the Randomized Phase III IMpassion050 Trial
2022 · Jens Huober, Carlos H. Barrios, et al. · Journal of Clinical Oncology · 138
Immune modulation of pathologic complete response after neoadjuvant HER2-directed therapies in the NeoSphere trial
2015 · G. Bianchini, L. Pusztai, et al. · Annals of Oncology · 132
Effect of Once-Weekly Epoetin Beta on Survival in Patients With Metastatic Breast Cancer Receiving Anthracycline- and/or Taxane-Based Chemotherapy: Results of the Breast Cancer—Anemia and the Value of Erythropoietin (BRAVE) Study
2008 · Matti Aapro, Robert C. Leonard, et al. · Journal of Clinical Oncology · 108
PDF
377O A pooled analysis of trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-positive (HER2+) metastatic breast cancer (mBC) with brain metastases (BMs) from DESTINY-Breast (DB) -01, -02, and -03
2023 · S.A. Hurvitz, S. Modi, et al. · Annals of Oncology · 59
PDF
A randomised phase II study of chemoradiotherapy with or without nimotuzumab in locally advanced oesophageal cancer: NICE trial
2017 · Gilberto de Castro Junior, José Getúlio Segalla, et al. · European Journal of Cancer · 57
A pooled analysis of trastuzumab deruxtecan in patients with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer with brain metastases
2024 · F. André, J. Cortés, et al. · Annals of Oncology · 55
PDF
DESTINY-Breast07: Dose-expansion interim analysis of T-DXd monotherapy and T-DXd + pertuzumab in patients with previously untreated HER2+ mBC.
2024 · Fabrice Andre, Erika P. Hamilton, et al. · Journal of Clinical Oncology · 35
Five-year analysis of the phase II NeoSphere trial evaluating four cycles of neoadjuvant docetaxel (D) and/or trastuzumab (T) and/or pertuzumab (P).
2015 · Luca Gianni, Tadeusz Pienkowski, et al. · Journal of Clinical Oncology · 35
Expression of alpha 1 and beta 3 integrins subunits in the endometrium of patients with tubal phimosis or hydrosalpinx
2006 · Ricardo Francalacci Savaris, José Luiz Pedrini, et al. · Fertility and Sterility · 33
CONFIRM: A Phase III, Randomized, Parallel-Group Trial Comparing Fulvestrant 250 mg vs Fulvestrant 500 mg in Postmenopausal Women with Estrogen Receptor-Positive Advanced Breast Cancer.
2009 · A. Di Leo, G. Jerusalem, et al. · Cancer Research · 21
Comparing duration of response and duration of clinical benefit between fulvestrant treatment groups in the CONFIRM trial: application of new methodology
2013 · Sally Anne Garnett, Miguel Martin, et al. · Breast Cancer Research and Treatment · 19
PDF
Are the Pure In Situ Breast Ductal Carcinomas and Those Associated With Invasive Carcinoma the Same?
2009 · Mario Casales Schorr, José Luiz Pedrini, et al. · Applied immunohistochemistry & molecular morphology · 18
Trastuzumab deruxtecan (T-DXd) vs trastuzumab emtansine (T-DM1) in patients (pts) with HER2+ metastatic breast cancer (mBC): Updated survival results of DESTINY-Breast03.
2024 · Erika P. Hamilton, Sara A. Hurvitz, et al. · Journal of Clinical Oncology · 13
A phase III, randomized, non-inferiority study comparing the efficacy and safety of biosimilar filgrastim versus originator filgrastim for chemotherapy-induced neutropenia in breast cancer patients
2016 · Roberto Hegg, André Mattar, et al. · Clinics · 13
The Effect of Neoadjuvant Chemotherapy on Hormone Receptor Status, HER2/neu and Prolactin in Breast Cancer
2011 · José Luiz Pedrini, Ricardo Francalacci Savaris, et al. · Tumori Journal · 13
Expressão da cox-2 e CD105 no câncer de mama e sobrevida livre de doença
2006 · Melina Grudzinski, Eduardo Cambruzzi, et al. · Revista da Associação Médica Brasileira · 8
PDF
Works count: 69
Citation count: 10,360
H-index: 19
I10-index: 24
Year
Topic
Type